@article{Faksova_K-2024_170365,
title = {COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals},
author = {Faksova, K. and Walsh, D. and Jiang, Y. and Griffin, J. and Phillips, A. and Gentile, A. and Kwong, J. and Macartney, K. and Naus, M. and Grange, Z. and Escolano, S. and Sepulveda, G. and Shetty, A. and Pillsbury, A. and Sullivan, C. and Naveed, Z. and Janjua, N. and Giglio, N. and Perälä, N. and Nasreen, S. and Gidding, H. and Hovi, P. and Vo, T. and Cui, F. and Deng, L. and Cullen, L. and Artama, M. and Lu, H. and Clothier, H. and Batty, K. and Paynter, J. and Petousis-Harris, H. and Buttery, J. and Black, S. and Hviid, A.},
month = {feb},
year = {2024},
abstract = {BackgroundThe Global COVID Vaccine Safety (GCoVS) Project, established in 2021 under the multinational Global Vaccine Data Network™ (GVDN®), facilitates comprehensive assessment of vaccine safety. This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries.},
journal = {Vaccine},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.vaccine.2024.01.100},
}
